Hearing Loss in a Patient with Waldenstrom Macroglobulinemia Receiving Bortezomib.

IF 0.7 Q4 ONCOLOGY
Case Reports in Oncology Pub Date : 2024-06-18 eCollection Date: 2024-01-01 DOI:10.1159/000539453
Jack Fitzsimons, Kathleen Phelan, Asha Dhanarajan
{"title":"Hearing Loss in a Patient with Waldenstrom Macroglobulinemia Receiving Bortezomib.","authors":"Jack Fitzsimons, Kathleen Phelan, Asha Dhanarajan","doi":"10.1159/000539453","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>We present a case report of hearing loss in a patient with Waldenstrom macroglobulinemia (WM) receiving treatment with bortezomib.</p><p><strong>Case presentation: </strong>Our patient developed sudden bilateral sensorineural hearing loss after receiving three doses of bortezomib. His hearing loss was irreversible and resulted in a cochlear implant.</p><p><strong>Conclusion: </strong>Hearing loss secondary to bortezomib is a known, but very rare, side effect. Hearing loss secondary to WM is also rare and has been described in case reports.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"17 1","pages":"653-657"},"PeriodicalIF":0.7000,"publicationDate":"2024-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11249454/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Case Reports in Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000539453","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: We present a case report of hearing loss in a patient with Waldenstrom macroglobulinemia (WM) receiving treatment with bortezomib.

Case presentation: Our patient developed sudden bilateral sensorineural hearing loss after receiving three doses of bortezomib. His hearing loss was irreversible and resulted in a cochlear implant.

Conclusion: Hearing loss secondary to bortezomib is a known, but very rare, side effect. Hearing loss secondary to WM is also rare and has been described in case reports.

接受硼替佐米治疗的瓦尔登斯特罗姆巨球蛋白血症患者的听力损失。
导言:我们报告了一例正在接受硼替佐米治疗的瓦尔登斯特罗姆巨球蛋白血症(WM)患者听力损失的病例:我们的患者在接受了三次硼替佐米治疗后突然出现双侧感音神经性听力损失。他的听力损失是不可逆的,因此需要植入人工耳蜗:结论:硼替佐米继发听力损失是一种已知但非常罕见的副作用。结论:硼替佐米继发听力损失是一种已知但非常罕见的副作用,继发于 WM 的听力损失也很罕见,在病例报告中已有描述。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.40
自引率
12.50%
发文量
151
审稿时长
7 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信